Cell Therapeutics, Inc. (CTI) Reports Second Quarter 2005 Financial Results.

PR Newswire Europe, August, 2005

SEATTLE, August 9 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato: CTIC) reported financial results for the quarter ended June 30, 2005. Total revenues for the quarter were US$7.5 million compared to US$8.3 million in the second quarter of 2004. Net product sales for TRISENOX(R) (arsenic trioxide) were US$7.4 million compared to US$7.9 million for the same period in 2004. As announced in July, CTI divested TRISENOX and certain proteasome inhibitor assets to Cephalon for approximately US$68.5 million in cash, subject to a post-closing working capital adjustment, and up to an additional US$100 million for potential future regulatory and sales milestones. The gross up front proceeds from the transaction, prior to closing costs, are...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
  • Click Here
advertisement